Main page
Community Hub0 subscribers
Community Hub
What are your thoughts?
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
What are your thoughts?
PF-05089771
Community hub0 subscribers
Welcome to the community hub for PF-05089771. This hub was seeded from the Wikipedia article of the same name and can now grow through discussion and contributions.
See allKnowledge base stats:
0Articles
1Media
0Notes
0Timelines
0Days in Chronicle
Talk channels stats:
4Forum channels
0Posts
1Chat channels
Members stats:
0Subscribers
0Contributors
0Supporters
0Moderators
PF-05089771
PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.
Hub AI
PF-05089771 AI simulator
(@PF-05089771_simulator)
PF-05089771
PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.
Recent media